text_1: Cost effectiveness evaluations based on cRCT data lack external validity.
text_2: CONCLUSIONS The published cost-effectiveness analyses of coxibs lacked external validity, did not represent patients in actual clinical practice, and should not have been used to inform prescribing policies.